- Home
- VVV vs BPMC Comparison
VVV vs BPMC Comparison
Compare VVV & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- BPMC
- Stock Information
- Founded
- VVV 1866
- BPMC 2008
- Country
- VVV United States
- BPMC United States
- Employees
- VVV N/A
- BPMC 655
- Industry
- VVV Major Chemicals
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- BPMC Health Care
- Exchange
- VVV Nasdaq
- BPMC Nasdaq
- Market Cap
- VVV 5.4B
- BPMC 5.6B
- IPO Year
- VVV 2016
- BPMC 2015
- Fundamental
- Price
- VVV $42.31
- BPMC $88.69
- Analyst Decision
- VVV Buy
- BPMC Buy
- Analyst Count
- VVV 8
- BPMC 19
- Target Price
- VVV $47.75
- BPMC $120.79
- AVG Volume (30 Days)
- VVV 918.1K
- BPMC 735.1K
- Earning Date
- VVV 11-19-2024
- BPMC 10-30-2024
- Dividend Yield
- VVV N/A
- BPMC N/A
- EPS Growth
- VVV N/A
- BPMC N/A
- EPS
- VVV 1.27
- BPMC N/A
- Revenue
- VVV $1,573,500,000.00
- BPMC $434,415,000.00
- Revenue This Year
- VVV $13.13
- BPMC $108.13
- Revenue Next Year
- VVV $12.61
- BPMC $38.91
- P/E Ratio
- VVV $27.96
- BPMC N/A
- Revenue Growth
- VVV 13.29
- BPMC 100.93
- 52 Week Low
- VVV $33.86
- BPMC $63.07
- 52 Week High
- VVV $48.27
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- VVV 53.25
- BPMC 43.37
- Support Level
- VVV $42.47
- BPMC $96.52
- Resistance Level
- VVV $43.20
- BPMC $103.55
- Average True Range (ATR)
- VVV 0.82
- BPMC 4.24
- MACD
- VVV 0.09
- BPMC 0.01
- Stochastic Oscillator
- VVV 59.41
- BPMC 35.04
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.